VUNO Med, Inc.

VUNO Med, Inc. develops AI-driven diagnostic and patient monitoring software solutions for healthcare providers. The company manufactures two principal FDA-cleared products: VUNO Med®-DeepCARS®, an early warning system for cardiac arrest risk assessment in general ward inpatients using vital signs monitoring (heart rate, blood pressure, respiratory rate, oxygen saturation, plus age and timing); and VUNO Med®-Chest X-ray™ Triage, an AI-based diagnostic support system for detecting suspected chest abnormalities and major pulmonary diseases from chest radiography. Both products integrate deep learning algorithms with clinical workflows to assist healthcare professionals in reducing response times, lowering clinical costs, and improving patient outcomes. The DeepCARS system has been prospectively validated in multicentre studies published in peer-reviewed journals including Critical Care Medicine and Resuscitation, demonstrating predictive value for in-hospital cardiac arrest and unplanned ICU transfer. The Chest X-ray Triage system has undergone external validation for detection of nodular and reticular opacities in interstitial lung disease and other pulmonary conditions. VUNO distributes its solutions primarily to hospitals and health systems in the United States and maintains clinical advisory relationships with leading academic medical centers. The company emphasizes regulatory compliance and clinical evidence to support adoption in acute care settings.